Robert Hendel, MD, discussed everything from declining reimbursements in cardiology to prior authorization policies in an exclusive new interview. 

Should interventional cardiologists be using X, the website formerly known as Twitter? A team of specialists explored that very question, sharing its assessment in JSCAI.

Eric Williamson, MD, a former SCCT president, examined recruitment and retention strategies for physicians and technologists in the field of cardiac CT. 

The company can now begin the enrollment process for its PROACTIVE-HF 2 clinical trial, which will focus on treating patients with NYHA class II heart failure. 

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

The subcutaneous administration of CBD could make a significant impact on patient outcomes, according to new findings presented at the Heart Failure Society of America's annual meeting in Cleveland.

Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.

The American College of Cardiology, Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons raised the issue, which is related to the billing of transcatheter heart procedures such as TAVR.